Progress in diagnosis and treatment of BKV-associated nephropathy in patients after kidney transplantation

doi:10.3877/cma.j.issn.2095-3216.2022.02.007

Abstract

Abstract:

BK virus (BKV) is a small DNA virus which is a common pathogen of infection after kidney transplantation. It establishes lifelong infections in the renal tubules and urothelial cells in most patients. Generally, the virus would not be activated and replicated after infecting healthy individuals. However, for immunocompromised patients such as kidney transplant recipients, BKV is easily reactivated and, in some cases, can lead to BKV-associated nephropathy (BKVAN). Due to the lack of specific antiviral agents, BKV infection remains an important risk factor for loss of graft function and recipient death. This article reviewed the current status and future development direction of the diagnosis, prevention, and treatment of BKVAN in recipients of kidney transplantation.

Key words: BK virus, BKV-associated nephropathy, Kidney transplantation, Immunosuppression, Diagnosis, Treatment

Fan Yang, Zhaohui Ni. Progress in diagnosis and treatment of BKV-associated nephropathy in patients after kidney transplantation[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2022, 11(02): 90-93.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2022.02.007

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2022/V11/I02/90

Figures/Tables 1

References 32

[1]	Chong S, Antoni M, Macdonald A, et al. BK virus: current understanding of pathogenicity and clinical disease in transplantation [J]. Rev Med Virol, 2019, 29(4): e2044.
[2]	中华医学会器官移植学分会. 器官移植受者BK病毒感染和BK病毒性肾病临床诊疗规范(2019版). 器官移植，2019, 10(3): 237-242.
[3]	Solis M, Gallais F, Velay A, et al. BK-virus and pathophysiology of associated diseases [J]. Virologie (Montrouge), 2019, 23(1): 7-22.
[4]	中华医学会器官移植学分会，中国医师协会器官移植医师分会. 中国实体器官移植受者BK病毒感染临床诊疗指南[J/CD]. 中华移植杂志(电子版), 2017, 11(2): 65-69.
[5]	Malik O, Saleh S, Suleiman B, et al. Prevalence, risk factors, treatment, and overall impact of BK viremia on kidney transplantation [J]. Transplant Proc, 2019, 51(6): 1801-1809.
[6]	Shah KV. Human polyomavirus BKV and renal disease [J]. Nephrol Dial Transplant, 2000, 15(6): 754-755.
[7]	Boldorini R, Allegrini S, Miglio U, et al. Serological evidence of vertical transmission of JC and BK polyomaviruses in humans [J]. J Gen Virol, 2011, 92(Pt 5): 1044-1050.
[8]	许瀚仁，王继纳，杨橙，等. 肾移植术后BK病毒感染与人肾小管上皮细胞的相关性研究进展[J]. 实用器官移植电子杂志，2021, 9(2): 169-172.
[9]	Kalluri HV, Sacha LM, Ingemi AI, et al. Low vitamin D exposure is associated with higher risk of infection in renal transplant recipients [J]. Clin Transplant, 2017, 31(5): e12955.
[10]	Wunderink HF, Haasnoot GW, de Brouwer CS, et al. Reduced risk of BK polyomavirus infection in HLA-B51-positive kidney transplant recipients [J]. Transplantation, 2019, 103(3): 604-612.
[11]	Plafkin C, Singh T, Astor BC, et al. Kidney transplant recipients with polycystic kidney disease have a lower risk of post-transplant BK infection than those with end-stage renal disease due to other causes [J]. Transpl Infect Dis, 2018, 20(6): e12974.
[12]	Manzano Sánchez D, Jimeno García L, Manzano Sánchez D, et al. Renal function impairment in kidney transplantation: importance of early BK virus detection [J]. Transplant Proc, 2019, 51(2): 350-352.
[13]	Hirsch HH, Knowles W, Dickenmann M, et al. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients [J]. N Engl J Med, 2002, 347(7): 488-496.
[14]	Elfadawy N, Yamada M, Sarabu N. Management of BK polyomavirus infection in kidney and kidney-pancreas transplant recipients: a review article [J]. Infect Dis Clin North Am, 2018, 32(3): 599-613.
[15]	Imlay H, Whitaker K, Fisher CE, et al. Clinical characteristics and outcomes of late-onset BK virus nephropathy in kidney and kidney-pancreas transplant recipients [J]. Transpl Infect Dis, 2018, 20(4): e12928.
[16]	Kamal M, Govil A, Anand M, et al. Severe BK polyomavirus-induced hemorrhagic cystitis in a kidney transplant recipient with the absence of renal allograft involvement [J]. Transpl Infect Dis, 2018, 20(1): 12814.
[17]	Hirsch HH, Randhawa PS, AST Infectious Diseases Community of Practice. BK polyomavirus in solid organ transplantation-guidelines from the American Society of Transplantation Infectious Diseases Community of Practice [J]. Clin Transplant, 2019, 33(9): e13528.
[18]	Brennan DC, Agha I, Bohl DL, et al. Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction [J]. Am J Transplant, 2005, 5(3): 582-594.
[19]	Laskin BL, Goebel J. Cost-efficient screening for BK virus in pediatric kidney transplantation: a single-center experience and review of the literature [J]. Pediatr Transplant, 2010, 14(5): 589-595.
[20]	Nickeleit V, Hirsch HH, Zeiler M, et al. BK-virus nephropathy in renal transplants-tubular necrosis, MHC-class II expression and rejection in a puzzling game [J]. Nephrol Dial Transplant, 2000，15(3): 324-332.
[21]	Batal I, Zainah H, Stockhausen S, et al. The significance of renal C4d staining in patients with BK viruria, viremia, and nephropathy [J]. Mod Pathol, 2009, 22(11): 1468-1476.
[22]	Sawinski D, Goral S. BK virus infection: an update on diagnosis and treatment [J]. Nephrol Dial Transplant, 2015, 30(2): 209-217.
[23]	Zhang X, Fu S, Han S, et al. The argument for the use of mizoribine in renal transplantation: a meta-analysis and systemic review [J]. Transpl Immunol, 2013, 28(2-3): 106-111.
[24]	Sharma R, Tzetzo S, Patel S, et al. BK virus in kidney transplant: current concepts, recent advances, and future directions [J]. Exp Clin Transplant, 2016, 14(4): 377-384.
[25]	Papanicolaou GA, Lee YJ, Young JW, et al. Brincidofovir for polyomavirus-associated nephropathy after allogeneic hematopoietic stem cell transplantation [J]. Am J Kidney Dis, 2015, 65(5): 780-784.
[26]	Gabardi S, Waikar SS, Martin S, et al. Evaluation of fluoroquinolones for the prevention of BK viremia after renal transplantation [J]. Clin J Am Soc Nephrol, 2010, 5(7): 1298-1304.
[27]	Knoll GA, Humar A, Fergusson D, et al. Levofloxacin for BK virus prophylaxis following kidney transplantation: a randomized clinical trial [J]. JAMA, 2014, 312(20): 2106-2114.
[28]	Randhawa PS, Schonder K, Shapiro R, et al. Polyomavirus BK neutralizing activity in human immunoglobulin preparations [J]. Transplantation, 2010, 89(12): 1462-1465.
[29]	Hirsch HH, Yakhontova K, Lu M, et al. BK polyomavirus replication in renal tubular epithelial cells is inhibited by sirolimus, but activated by tacrolimus through a pathway involving FKBP-12 [J]. Am J Transplant, 2016, 16(3): 821-832.
[30]	Schold JD, Rehman S, Kayler LK, et al. Treatment for BK virus: incidence, risk factors and outcomes for kidney transplant recipients in the United States [J]. Transpl Int, 2009, 22(6): 626-634.
[31]	Cohen-Bucay A, Ramirez-Andrade SE, Gordon CE, et al. Advances in BK virus complications in organ transplantation and beyond [J]. Kidney Med, 2020, 2(6): 771-786.
[32]	熊睿，丁利民，杨华，等. 肾移植术后高水平BK病毒尿症危险因素分析[J]. 器官移植，2021, 12(3): 317-323.

日期	ALT(U/L)	AST(U/L)	肌酐(μmol/L)	尿液BKV DNA(拷贝/ml)	用药方案
07-15	128	53	91.0	8.56×10³	停用来氟米特改为环孢素100 mg+骁悉0.5 g均2次/d
07-20	93	35	85.0	3.25×10³	环孢素125 mg+咪唑立宾50 mg均2次/d
08-10	27	19	85.0	<2 000	他克莫司缓释片2 mg+咪唑立宾50 mg均2次/d

日期	ALT(U/L)	AST(U/L)	肌酐(μmol/L)	尿液BKV DNA(拷贝/ml)	用药方案
07-15	128	53	91.0	8.56×10³	停用来氟米特改为环孢素100 mg+骁悉0.5 g均2次/d
07-20	93	35	85.0	3.25×10³	环孢素125 mg+咪唑立宾50 mg均2次/d
08-10	27	19	85.0	<2 000	他克莫司缓释片2 mg+咪唑立宾50 mg均2次/d

Please choose a citation manager

Content to export